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Subcutaneous Sarilumab in Patients With Rheumatoid 
Arthritis who Previously Received Subcutaneous Sarilumab 
or Intravenous Tocilizumab: An Open-Label Extension of a 
Randomized Clinical Trial
Paul Emery,1  Hubert van Hoogstraten,2 Karthinathan Thangavelu,3 Erin Mangan,4 Gregory St John,4 and 
Patrick Verschueren5
Objective. This post hoc analysis evaluated the safety and efficacy of open-label sarilumab in patients with 
rheumatoid arthritis (RA) who completed the phase III double-blind ASCERTAIN study (NCT01768572) and switched 
from intravenous (IV) tocilizumab to subcutaneous (SC) sarilumab, or who continued SC sarilumab in the open-label 
extension (OLE) study EXTEND (NCT01146652).
Methods. Patients who completed ASCERTAIN were eligible to enroll in EXTEND to receive sarilumab 200 mg SC 
every 2 weeks (Q2W). Safety and efficacy were reported through 96 weeks in the OLE in patients who switched from 
tocilizumab IV to sarilumab 200 mg SC Q2W, who switched from sarilumab 150 mg SC Q2W to sarilumab 200 mg SC 
Q2W, or who continued sarilumab 200 mg SC Q2W.
Results. Of 175 patients who completed ASCERTAIN, 168 (96%) enrolled in EXTEND, and 38 of these patients 
(23%) discontinued the OLE. Cumulative sarilumab exposure during follow-up was 273.7 patient-years. No new 
safety signals were identified, infections occurred at a rate of 59.9/100 patient-years, and there were no cases of 
grade 4 neutropenia. Efficacy—as assessed by Disease Activity Score (28 joints) based on C-reactive protein, Clinical 
Disease Activity Index, and Health Assessment Questionnaire-Disability Index scores—was sustained over 96 weeks 
of follow-up when switching to, or continuing, sarilumab 200 mg SC Q2W.
Conclusion. Switching from IV to SC interleukin-6 receptor inhibitor therapy produced no new safety concerns, 
and clinical efficacy was sustained over 96 weeks of follow-up. These findings alleviate potential concerns over 
switching route of administration with interleukin-6 receptor inhibitor therapy for RA.
INTRODUCTION
Sarilumab is a human monoclonal antibody that binds to 
both the membrane-bound and soluble forms of the interleukin-6 
receptor (IL-6R), and functions to inhibit IL-6 signaling (1). It is 
approved for the treatment of moderately to severely active rheu-
matoid arthritis (RA) in adult patients who have had an inadequate 
response to, or intolerance of, one or more disease-modifying 
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antirheumatic drugs (DMARDs), and it can be used either as mono-
therapy or concomitantly with methotrexate or other conventional 
synthetic DMARDs (csDMARDs) (1). Sarilumab has demonstrated 
clinical and radiographic benefits in adult patients with RA in 
active-comparator and placebo-controlled phase III trials, both as 
a monotherapy and in combination with csDMARDs (2–5). Tocili-
zumab is a humanized recombinant monoclonal antibody that tar-
gets membrane-bound and soluble IL-6R and is approved for the 
treatment of RA (6).
The phase III ASCERTAIN study (NCT01768572) was a 
24-week, randomized, double-blind, double-dummy, three-arm, 
parallel-group safety study in patients with active RA who had an 
inadequate response to a prior tumor necrosis factor inhibitor and 
were receiving csDMARD treatment (2). The study demonstrated 
that sarilumab and tocilizumab were each well tolerated and had 
similar safety profiles. Sarilumab was administered by subcutane-
ous (SC) injection, and tocilizumab was administered intravenously 
(IV) according to its US product labeling at the time the study was 
conducted (6). After the double-blind randomized control phase 
(RCT), patients were eligible to enroll in the ongoing open-label 
extension (OLE) study, EXTEND (NCT01146652). EXTEND is a 
5-year extension study to assess the long-term safety and efficacy 
of sarilumab SC in patients with RA who previously participated in 
one of several shorter-term sarilumab studies (2,4,7,8). Data pre-
sented here show only those patients in EXTEND who enrolled 
from the ASCERTAIN RCT. Patients who received tocilizumab IV 
plus placebo SC in the RCT switched to sarilumab SC on enroll-
ment into the OLE. This switch made it possible to investigate the 
effects of switching from IV to SC IL-6R inhibition in a clinical trial 
setting. The aim of this post hoc analysis was to evaluate the safety 
and efficacy of switching from double-blind, double-dummy tocili-
zumab IV or sarilumab SC to open-label sarilumab SC in the OLE.
PATIENTS AND METHODS
Ethics approval. The protocol was approved by the appro-
priate ethics committees/institutional review boards: London - 
Brighton & Sussex Research Ethics Committee (approval number 
13/LO/0499) and from each of the 85 additional study centers 
in Europe (including Russia), North America, and South America. 
Each patient gave written informed consent before study partici-
pation. The study was conducted in compliance with institutional 
review board regulations, the International Conference on Harmo-
nization Guidelines for Good Clinical Practice, and the Declaration 
of Helsinki.
Study design. In ASCERTAIN, patients were randomized 
1:1:2 to receive sarilumab 150 mg SC every 2 weeks (Q2W), sari-
lumab 200 mg SC Q2W, or tocilizumab 4 mg/kg IV every 4 weeks 
(Q4W) (2). In instances of an insufficient response to tocilizumab 
4  mg/kg IV Q4W, the dose could be increased to 8  mg/kg IV 
Q4W at the investigator’s discretion, per US label instructions (6). 
EXTEND is a multicenter OLE study designed to assess the long-
term safety and efficacy of sarilumab SC in adult patients with RA, 
including in patients who completed the ASCERTAIN study. All 
patients who completed the parent study were eligible for inclu-
sion in the OLE. Patients entering the OLE received sarilumab 
200 mg SC Q2W.
Assessments. OLE baseline was defined as the start of 
the OLE (visit 1, week 0). Safety data were reported from patient 
visit 1 to visit 14 (OLE week 96) for all patients who entered the 
OLE. Visits occurred Q2W until OLE week 12 and every 12 weeks 
thereafter until OLE week 96. Assessments included the record-
ing of treatment-emergent adverse events (AEs) and laboratory 
investigations, including absolute neutrophil counts and liver func-
tion tests. Samples for laboratory investigations were taken at 
each visit. AEs were described using the Medical Dictionary for 
Regulatory Activities (version 20.0) preferred terms. AEs of special 
interest were collected according to predefined criteria, specific to 
scientific and medical concerns of the drugs involved.
Efficacy assessments—using the Disease Activity Score 
(28 joints) based on C-reactive protein (DAS28-CRP), Clinical 
Disease Activity Index (CDAI), and Health Assessment Question-
naire-Disability Index (HAQ-DI)—were made at each study visit. 
Continuous efficacy outcomes are presented as observed cases 
(OCs) without imputation of missing data as mean score (±SE). 
Disease activity thresholds were DAS28-CRP < 2.6 or < 3.2, CDAI 
≤ 2.8 or ≤ 10, and HAQ-DI score improvement of ≥0.3 from score 
at RCT baseline. The proportions of patients achieving DAS28-CRP, 
CDAI, or HAQ-DI disease activity thresholds at weeks 12 and 96 are 
presented in two ways: (a) based on the number of patients assessed 
at each visit (OC approach) or (b) based on the intention-to-treat 
(ITT) population approach, with patients for whom data were missing 
counted as nonresponders (nonresponder imputation).
Data in the OLE were compared according to patients’ origi-
nal treatment groups in the RCT: sarilumab 150 mg SC Q2W, sar-
ilumab 200 mg SC Q2W, or tocilizumab 4 mg/kg IV Q4W received 
throughout the RCT, or tocilizumab 4 mg/kg IV Q4W increased to 
8 mg/kg IV Q4W at week 4 of the RCT and continuing at 8 mg/kg 
IV Q4W thereafter (referred to as the tocilizumab 4/8  mg/kg 
group). Data from the OLE were also grouped into all sarilumab 
patients and all tocilizumab patients. To maintain consistency 
within the groups, patients who changed tocilizumab dose after 
week 4 were not included in the tocilizumab 4 mg/kg group or the 
4/8 mg/kg group, but only in the all-tocilizumab group. Data were 
analyzed using descriptive statistics only.
Patient and public involvement. The clinical trial was 
recorded on public registry websites prior to the enrollment of the 
first patient. This research was done without patient consultation. 
At the time that this study was conducted, there were no funds 
or time allocated for patient/public involvement in study design or 
result-dissemination planning.
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RESULTS
Patient population. Of the 175 patients who completed 
the RCT, 168 (96%) enrolled in the OLE. A similar number of 
patients enrolled from each RCT treatment group: sarilumab 
150 mg (n = 37, 22% of patients in the OLE), sarilumab 200 mg 
(n = 38, 23%), tocilizumab 4  mg/kg (n = 35, 21%), and tocili-
zumab 4/8 mg/kg (n = 38, 23%). An additional 20 patients who 
changed tocilizumab dosage after week 4 of the parent study 
were included in the all-tocilizumab group, so the tocilizumab 
4/8 mg/kg group was consistent in containing only patients who 
changed dose from 4 to 8 mg/kg IV Q4W at week 4 and remained 
on tocilizumab 8 mg/kg IV Q4W thereafter. Patient demographic 
and most disease characteristics were well balanced across all 
groups, although, compared with other treatment groups, base-
line CRP levels were elevated in patients who had received only 
tocilizumab 4  mg/kg for 24 weeks and were not escalated to 
8 mg/kg during the RCT (Table 1).
Safety. Overall, 38 patients (23%) discontinued the OLE 
study before week 96. Discontinuations due to AEs were reported 
for 22 patients (13%). Discontinuations for reasons other than 
safety included 5 patients (3%) due to lack of efficacy and 1 
patient (1%) due to poor compliance with the protocol; 14 patients 
(8%) requested treatment discontinuation (Figure 1). Overall dis-
continuation rates were similar across the prior treatment groups 
in the RCT, except in the tocilizumab 4/8 mg/kg group, which had 
a greater number of discontinuations, mainly due to patient-re-
quested discontinuations (n = 7, 18%). Three deaths of patients 
Table 1. Demographics and baseline disease characteristics
Treatment During the RCT, Before Switch to Sarilumab 200 mg SC Q2W in the OLE
Sarilumab 
150 mg SC Q2W 
(n = 37)
Sarilumab 
200 mg SC Q2W 
(n = 38)
Tocilizumab 
4 mg/kg IV Q4Wa 
(n = 35)
Tocilizumab 





Recorded at RCT baseline
Female, n (%) 30 (81.1) 31 (81.6) 29 (82.9) 31 (81.6) 76 (81.7)
Duration of RA since diagnosis (y),  
 mean (SD)
12.9 (7.3) 8.8 (6.0) 9.1 (7.3) 11.5 (7.8) 9.9 (7.9)
ACR RA functional class, n (%)
I 6 (16.2) 3 (7.9) 6 (17.1) 3 (7.9) 13 (14.0)
II 20 (54.1) 24 (63.2) 24 (68.6) 21 (55.3) 58 (62.4)
III 11 (29.7) 11 (28.9) 5 (14.3) 14 (36.8) 22 (23.7)
IV 0 0 0 0 0
RF positive, n (%) 29 (80.6)d 23 (60.5) 28 (80.0) 30 (81.1)e 73 (79.3)f
ACPA positive, n (%) 32 (88.9)d 30 (78.9) 28 (80.0) 31 (91.2)g 76 (86.4)h
Recorded at OLE baseline, mean (SD)
Age, y 53.5 (10.8) 52.2 (11.5) 51.2 (13.3) 50.1 (12.0) 50.4 (12.8)
BMI, kg/m2 27.1 (5.1) 29.3 (6.8) 29.2 (4.3) 27.4 (6.1) 28.0 (5.3)
Nonbiologic DMARD use, n (%) 37 (100) 37 (97.4) 35 (100) 37 (97.4) 92 (92.9)
Glucocorticoid use, n (%) 16 (43.2) 15 (39.5) 19 (54.3) 23 (60.5) 49 (52.7)
Disease activity at OLE baseline
Tender joint count (0–68) 7.1 (8.9) 7.2 (8.7) 4.5 (4.8) 7.5 (7.9) 6.3 (7.2)
Swollen joint count (0–66) 3.1 (3.5) 4.5 (6.4) 3.3 (3.4) 3.9 (3.8) 4.0 (4.8)
CRP (mg/L) 5.4 (13.8)d 2.2 (5.3) 14.1 (16.4)g 3.1 (8.4) 6.7 (12.6)f
DAS28-CRP 3.0 (1.2)d 3.0 (1.2) 3.3 (1.2)g 3.2 (1.1) 3.2 (1.2)f
CDAI 11.9 (10.3) 13.0 (11.8) 10.6 (7.5) 13.7 (9.0) 12.4 (9.5)
HAQ-DI (0–3) 1.1 (0.6) 1.2 (0.6) 1.0 (0.8) 1.3 (0.7) 1.2 (0.7)
Abbreviations: ACPA, anticyclic citrullinated peptide antibody; ACR, American College of Rheumatology; BMI, body mass index; CDAI, Clinical 
Disease Activity Index; CRP, C-reactive protein; DAS28-CRP, Disease Activity Score (28 joints) based on CRP; HAQ-DI, Health Assessment 
Questionnaire-Disability Index; IV, intravenous; OLE, open-label extension; Q2W, every 2 weeks; Q4W, every 4 weeks; RA, rheumatoid arthritis; 
RCT, double-blind randomized control phase; RF, rheumatoid factor; SC, subcutaneous; SD, standard deviation.
a Patients received tocilizumab 4 mg/kg IV Q4W at baseline in the RCT and remained at this dose throughout. 
b Patients received tocilizumab 4 mg/kg IV Q4W at baseline in the RCT and switched at week 4 to tocilizumab 8 mg/kg IV Q4W for the remainder 
of the study. 
c Included n = 20 patients who changed tocilizumab dose after week 4 of the RCT. 
d n = 36. 
e n = 7. 
f n = 92. 
g n = 34. 
h n = 88. 
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treated with open-label sarilumab were recorded during the OLE: 
one in the original sarilumab 150 mg RCT group (cervical can-
cer), one in the original sarilumab 200 mg RCT group (colorectal 
cancer), and one in the original tocilizumab 4 mg/kg RCT group 
(psoas abscess; Table 2).
The overall incidence and exposure-adjusted rates of 
investigator-reported AEs during the OLE were similar among 
groups (Table 2). No new safety signals emerged in patients 
who switched from tocilizumab IV to sarilumab SC, nor during 
longer-term treatment in those continuing sarilumab. The most 
common AEs (greatest percentages of patients with at least one 
event) were neutropenia (19.4/100 patient-years [PY] overall), 
upper respiratory tract infections (8.8/100 PY), and urinary tract 
infections (6.6/100 PY). The most common AEs of special inter-
est were infections (59.9/100 PY overall), injection-site reactions 
(42.4/100 PY), and leukopenia (23.7/100 PY; Supplementary 
Table 1). Serious infections occurred at a rate of 3.3/100 PY. 
The incidence of leukopenia was similar across groups. There 
was one upper gastrointestinal (GI) perforation in the OLE (RCT 
tocilizumab 4 mg/kg group) but no lower GI perforations. Malig-
nancies occurred in five patients (1.8/100 PY), three of which 
were nonmelanoma skin cancer, one was cervical cancer, and 
one was colorectal cancer.
Incidence of investigator-reported neutropenia was generally 
similar across groups (Table 2). Protocolled laboratory investiga-
tions detected absolute neutrophil count (ANC) nadir of ≥500 to 
1000 cells/mm3 (grade 3 neutropenia) in 17 patients overall (10.1%; 
Supplementary Table 2). No patients had ANC < 500 cells/mm3 
(grade 4 neutropenia). Liver function test abnormalities were sim-
ilar across groups, with 10 patients (6.0%) exhibiting alanine ami-
notransferase (ALT) > 3 × the upper limit of normal and 2 patients 
(1.2%) exhibiting ALT >  5 × the upper limit of normal (Supple-
mentary Table 3). There were no cases of Hy’s law (drug-induced 
liver injury). Investigator-reported lipid elevations occurred with an 
incidence rate of 6.9/100 PY (Supplementary Table 1).
Efficacy. Mean DAS28-CRP, CDAI, and HAQ-DI scores 
were generally sustained over 96 weeks of follow-up in patients 
who switched from tocilizumab 4 or 4/8 mg/kg IV Q4W, or who 
remained on sarilumab SC (Figure 2). In patients with low disease 
activity (DAS28-CRP < 3.2 or CDAI ≤ 10) at entry into the OLE, 
low disease activity thresholds were largely maintained through 
week 96 of the OLE (Figure 3). A small number of patients who did 
not achieve low disease activity at the end of the RCT achieved 
low disease activity during the OLE (Supplementary Table 4). Sim-
ilar results were observed for other disease activity thresholds 
(Supplementary Figure 1; Supplementary Table 4).
DISCUSSION
In this study, patients who switched from IV to SC adminis-
tration of IL-6R inhibitors for treatment of RA experienced sus-
tained tolerability and efficacy. No new safety signals emerged 
during the OLE in patients who switched from tocilizumab IV 
Figure 1. Patient disposition through the OLE. Abbreviations: IV, intravenous; OLE, open-label extension; Q2W, every 2 weeks; Q4W, every 
4 weeks; RCT, double-blind randomized control phase; SC, subcutaneous.
aPatients requesting discontinuation is not additive with the number of patients who discontinued. [Color figure can be viewed at wileyonlinelibrary.
com]






200 mg SC Q2W
8 (21.6%) patients discontinued
• 4 (10.8%) – Adverse event
• 1 (2.7%) – Lack of efficacy
• 3 (8.1%) – Other reasons
4 (10.8%) – Patients requested
discontinuationa
29 (78.4%) patients
continued OLE to 96
weeks




200 mg SC Q2W
8 (21.1%) patients discontinued
• 6 (15.8%) – Adverse event
• 1 (2.6%) – Lack of efficacy
• 1 (2.6%) – Other reasons
1 (2.6%) – Patients requested
discontinuationa
30 (78.9%) patients
continued OLE to 96
weeks
Tocilizumab 4 mg/kg IV Q4W




200 mg SC Q2W
6 (17.1%) patients discontinued
• 5 (14.3%) – Adverse event
• 1 (2.9%) – Other reasons
1 (2.9%) – Patients requested
discontinuationa
29 (82.9%) patients









200 mg SC Q2W
22 (23.7%) patients discontinued
• 12 (12.9%) – Adverse event
• 3 (3.2%) – Lack of efficacy
• 1 (1.1%) – Poor compliance
      with protocol
• 6 (6.5%) – Other reasons
9 (9.7%) – Patients requested
discontinuationa
71 (76.3%) patients
continued OLE to 96
weeks
Tocilizumab 4→8 mg/kg
IV Q4W at week 4, then





200 mg SC Q2W
14 (36.8%) patients discontinued
• 6 (15.8%) – Adverse event
• 2 (5.3%) – Lack of efficacy
• 1 (2.6%) – Poor compliance
      with protocol
• 5 (13.2%) – Other reasons
7 (18.4%) – Patients requested
discontinuationa
24 (63.2%) patients
continued OLE to 96
weeks
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to sarilumab SC, nor during longer-term treatment in those 
continuing sarilumab. Clinical efficacy was generally sustained 
after switching to sarilumab SC across the whole patient cohort 
through 96 weeks of follow-up, regardless of initial treatment in 
the RCT.
There is a trend for increasing use of SC over IV admin-
istration in RA (9,10), and evidence that both physicians and 
patients prefer SC therapy over IV (11–13). The convenience 
of home treatment, faster treatment time, lower costs, reduced 
travel time, and fewer visits to clinics or hospitals were all cited 
Figure 2. Mean (±SE) efficacy scores from OLE baseline to week 96 in overall patient population (observed cases) for DAS28-CRP (A, B), 
CDAI (C, D), and HAQ-DI (E, F). Abbreviations: CDAI, Clinical Disease Activity Index; DAS28-CRP, Disease Activity Score (28 joints) based 
on C-reactive protein; HAQ-DI, Health Assessment Questionnaire-Disability Index; IV, intravenous; OLE, open-label extension; Q2W, every 2 














































Prior treatment Number of subjects
Sarilumab 150 mg 36 35 32 35 34 34 33 33 30 29 28
Sarilumab 200 mg 38 36 37 35 36 36 35 32 33 32 32
All sarilumab 74 71 69 70 70 70 68 65 63 61 60
Prior treatment 
Sarilumab 150 mg 37 36 35 36 35 35 34 34 31 30 29
Sarilumab 200 mg 38 38 37 36 36 36 35 32 33 33 32
All sarilumab 75 74 72 72 71 71 69 66 64 63 61
Prior treatment 
Sarilumab 150 mg 37 36 35 36 35 35 34 34 31 29 29
Sarilumab 200 mg 38 37 37 37 36 36 35 33 33 33 32
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Prior treatment Number of subjects
Number of subjects
Number of subjects Number of subjects
Number of subjects
Tocilizumab 4 mg/kg 34 34 34 32 30 30 28 28 28 28 28
Tocilizumab 4/8 mg/kg 38 38 38 37 36 32 31 30 29 27 25
All tocilizumab 92 91 91 87 85 81 78 77 76 73 71
Prior treatment 
Tocilizumab 4 mg/kg 35 35 35 33 31 31 30 29 29 29 29
Tocilizumab 4/8 mg/kg 38 38 38 37 35 32 31 30 29 27 25
All tocilizumab 93 91 92 88 85 82 80 78 77 74 72
Prior treatment 
Tocilizumab 4 mg/kg 35 35 35 34 31 31 30 29 29 29 29
Tocilizumab 4/8 mg/kg 38 38 38 37 36 32 31 30 29 27 25
All tocilizumab 93 92 92 89 86 82 80 78 77 74 72
Prior treatment Treatment in OLE
Sarilumab 
200 mg SC Q2W
Tocilizumab 4 mg/kg IV Q4W
Tocilizumab 4/8 mg/kg IV Q4W
All tocilizumab
Sarilumab 150 mg SC Q2W
Sarilumab 200 mg SC Q2W
All sarilumab
Prior treatment Treatment in OLE
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as advantages of SC treatment versus IV, though some patients 
preferred IV treatment because it meant administration by 
a medical professional and interaction with other patients during 
treatment (11,12,14–19). There is also an association between 
requirements for longer-term treatment and patient preference for 
SC therapy (13), which is an important consideration for the man-
agement of a chronic condition such as RA. In this and other 
studies of patients with RA, patients who switched from IV to 
SC therapy generally maintained SC treatment after switching 
(20,21), which suggests that SC treatment was as satisfactory 
as IV. The results presented here offer reassurance to physicians 
and patients considering a switch in route of administration for 
IL-6R inhibitor therapy for RA and are consistent with evidence of 
continued efficacy and safety following IV to SC switch with other 
RA therapies (10,20,22,23).
The safety profile in patients who switched to open-label sar-
ilumab 200 mg Q2W was generally consistent with that observed 
for sarilumab 200 mg Q2W treatment during the RCT (2), with 
previous analyses of phase III studies of sarilumab (4,5,7,24), and 
with the safety profile expected of IL-6 inhibition (25). Incidences 
of elevated levels of ALT and other markers of liver function were 
comparable across all groups and consistent with those in pre-
vious studies (2,4). The small number of patients who reported 
injection-site reactions according to the composite AESI term 
(n = 4-5 in each group) does not support firm conclusions. How-
ever, the uniformity of the administration method across groups 
(“double-dummy, double-blind” SC and IV injections before 
switch; open-label sarilumab after switch) might explain the rel-
atively uniform proportion of patients reporting injection-site reac-
tions after switch.
Figure 3. Percentage of patients (OC and ITT) who achieved disease activity thresholds at OLE baseline and sustained them following switch 
to open-label sarilumab at OLE weeks 12 and 96. Abbreviations: CDAI, Clinical Disease Activity Index; DAS28-CRP, Disease Activity Score (28 
joints) based on C-reactive protein; ITT, intention-to-treat patient population; IV, intravenous; OC, observed case patient population; OLE, open-
label extension; Q2W, every 2 weeks; Q4W, every 4 weeks; SC, subcutaneous. aUses the number of patients assessed at each time point as 
the denominator for the percentage of patients achieving disease activity thresholds at each time point. bUses the number of patients achieving 
disease activity thresholds at OLE baseline as the denominator for the percentage of patients achieving disease activity thresholds at each time 
point. [Color figure can be viewed at wileyonlinelibrary.com]
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The observation that baseline CRP levels were higher after tocili-
zumab 4 mg/kg IV Q4W compared with patients who received tocili-
zumab 8 mg/kg IV Q4W, or sarilumab 150 or 200 mg SC (despite 
similar CRP levels at the start of the randomization) (2), is consistent 
with other studies that have shown dose-dependent and potential 
suboptimal suppression of CRP with the lower tocilizumab dose (26).
Efficacy was generally sustained in patients who continued 
from sarilumab in the RCT to open-label sarilumab in the OLE. 
There have been concerns that unblinding patients following com-
mencement of open-label treatment may introduce bias due to 
altered perceptions in patient self-reporting or changes in placebo 
effects (27). These issues do not seem to have had an effect on 
the outcomes in the present study, in which clinical assessment 
scores remained stable in the sarilumab continuation groups after 
switching to open-label sarilumab. The proportion of patients who 
achieved disease activity thresholds (DAS28-CRP < 2.6 or < 3.2, 
CDAI ≤ 2.8 or ≤ 10, or HAQ-DI score improvement ≥ 0.3) at the 
end of the RCT was also generally stable through 96 weeks of 
follow-up in the OLE study after switching to open-label sarilumab 
200 mg SC Q2W, regardless of initial treatment in the RCT.
A subset of patients who did not achieve disease activity 
thresholds at the end of the RCT subsequently achieved them fol-
lowing a switch to open-label sarilumab. These improvements in dis-
ease activity postswitch may be attributed to a number of reasons, 
including late response to anti–IL-6R treatment, positive effects 
resulting from the change to an open-label treatment in the OLE, or 
unknown mechanistic differences between the two therapies.
Limitations of this study include that it is a post hoc evaluation 
of a relatively small subpopulation of patients from the EXTEND OLE 
trial, with no formal statistical analysis. The switch to sarilumab was 
performed in an OLE, which has the potential to introduce a positive 
bias into the treatment population. This can occur because patients 
become aware that they are receiving the optimal dose of the exper-
imental treatment option. Bias can also occur because the OLE dis-
counts noncompleters in the RCT section of the study, which can 
enrich the study population with patients who tolerate and respond 
well to treatment. This can lead to a progressively smaller pool of 
patients, most of whom have a positive treatment response. To 
overcome this bias, we reported proportions of patients using ITT 
analysis as well as OC analysis.
In conclusion, switching from double-blind tocilizumab IV 
or sarilumab SC to open-label sarilumab SC produced no new 
safety concerns and demonstrated sustained clinical efficacy over 
96 weeks, as shown by the durability of treatment effect. The 
safety profile of sarilumab in the OLE was generally consistent with 
that seen in the RCT, with long-term sarilumab treatment, and with 
the anticipated profile of an IL-6 inhibitor.
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